Navigation Links
Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Date:2/15/2008

tere(R) (docetaxel) chemotherapy plus prednisone in HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. An interim analysis of the trial was recently conducted by an independent data monitoring committee in the timeframe originally estimated and resulted in the recommendation to continue the trial. The company expects to have enough events to trigger the final analysis of VITAL-1 in the second half of 2009. VITAL-2, which the company expects to fully enroll with approximately 600 patients in the first half of 2009, is designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. The company expects to have enough events to trigger an interim analysis of VITAL-2 in the first half of 2009.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational products comprised of whole tumor cells that have been modified to secrete GM- CSF (granulocyte-macrophagecolony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety. GVAX is administered via intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GVAX immunotherapy for prostate cancer in its bioreactor-based manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product for commercialization.

About Cell Genesys

Cell Genesys is focused on the development and comme
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
2. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
7. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Second Thoughts about Fluoride, Reports Scientific American
11. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... 21, 2014 Professional Compounding Centers of ... by awarding the three best scientific presentations at ... conference . The Formulating Better Medicines for ... Athens, Greece , includes dozens ... professionals, from which three winners will be selected ...
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3
... Dec 13, 2011 MedEfficiency, Inc., a medical ... manufacturing, and marketing of medical devices for treating ... that it has been awarded a Veteran,s Administration ... will be listed as a government-approved vendor.  ...
... More than 60,000 young children end up in emergency ... parents or caregivers were not looking. To remind parents ... the Centers for Disease Control and Prevention (CDC) and ... partnership with the PROTECT Initiative , today launched ...
Cached Medicine Technology:MedEfficiency Awarded VA Contract for Its Total Contact Casting Products 2CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 2CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 3
(Date:8/21/2014)... 2014 (HealthDay News) -- Not only is eating better and ... hundreds of health-care dollars a year, a new study finds. ... public health sciences at Wake Forest Baptist Medical Center in ... type 2 diabetes patients. Participants ranged in ... either an intensive "lifestyle change program" focused on diet and ...
(Date:8/21/2014)... The W. Montague Cobb/ NMA Health ... voice in the elimination of health disparities, honored ... 112th National Medical Association’s (NMA) Annual Convention and ... Ruffin, Ph.D, former Director of the National Institute ... career and innovations have had a significant impact ...
(Date:8/21/2014)... to focus on her body in terms of how ... as a complete human being with thoughts and feelings. ... the media, how does it affect individual romantic relationships? ... , a SAGE journal, finds that more objectification of ... of sexual pressure and coercion., Researchers Laura R. Ramsey ...
(Date:8/21/2014)... 21, 2014 Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... to suffer uncontrollable internal bleeding and other serious injuries ... reports. According to court documents, a wrongful death lawsuit ... Easter District of New York by the family of ... event that was allegedly caused by Xarelto. Among other ...
(Date:8/21/2014)... 21, 2014 According to a new ... Equipment (Product Types - Home Theatre in-a-box, Home audio ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... 15.94 billion in 2012 and is expected to reach ... of 3.7% from 2013 to 2019. Europe was the ...
Breaking Medicine News(10 mins):Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3
... has become habitual for the elders to slip into the ... their youth, but psychologists warn// that such frequent reminiscing of ... ,This phenomenon becomes a problem when an elderly relative starts ... some might welcome a break from older relatives repeating boring ...
... hormone called brain natriuretic peptide can predict the presence ... according to a study appearing in the April issue ... Medicine, published by the American Thoracic Society. ,Juergen ... the Department of internal medicine at Ludwig Maximillians University ...
... conducted to test the drug manufactured by German pharmaceutical company ... drug TGN1412 which was designed to treat rheumatoid arthritis, leukaemia ... One of six men who fell seriously ill after taking ... he felt like his brain was on fire. Student Nav ...
... been shown that babies who were given an aid to ... and is safe. The way was CNEP therapy - continuous ... by unconnected Nottingham researchers to the original trial in the ... paediatrician Professor David Southall. ,The Nottingham researchers followed ...
... old baby was charred to death due to a short circuit ... joy and hopes. The incubator in which the baby was kept ... had happened due to negligence of the hospital staff while the ... saved due to prompt action of the medical staff who switched ...
... California officials are expecting bird flu arrive at the U.S. ... sign in the United States of the deadly virus. // ... Europe and down to Africa. This announcement was made by ... on Thursday at a state bird flu pandemic preparedness meeting. ...
Cached Medicine News:Health News:Reminiscing Into The Past Makes You Dissatisfied With The Present 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 3Health News:The Face Of Indian Health Care: A World Health Day Evaluation 4Health News:Bird Flu Expected To Hit U.S. This Summer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: